ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1517

Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis

Iain McInnes1, Dafna Gladman 2, Atul Deodhar 3, Corinne Miceli-Richard 4, Peter Nash 5, Naveed Sattar 6, Nehal Mehta 7, Darren Asquith 8, Jianyuan Wang 9, Hanno Richards 9, Luminita Pricop 10 and Abhijit Shete 9, 1Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 3Oregon Health & Science University, Portland, OR, 4Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, 5University of Queensland, Brisbane, Queensland, Australia, 6Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, 7National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, 8Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom, 9Novartis Pharma AG, Basel, Switzerland, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: , , ,

Session Information

Date: Monday, November 11, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic inflammation may influence cardio-metabolic profiles and increases the risk of CV disorders in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients (pts)1. Treatment with tumor necrosis factor (TNF) and Janus Kinase inhibitors have reported increased total cholesterol (TC) and triglycerides (TG) despite reduction in inflammation2,3. Here, we present the long-term effect of secukinumab (SEC), a fully human monoclonal antibody that directly inhibits interleukin (IL) -17A, on key cardio-metabolic parameters in AS and PsA pts from a pooled analysis of phase 3 clinical trials, through 156 weeks (wks).

Methods: This post hoc analysis pooled data from MEASURE 1−4 studies in AS (N=892) and FUTURE 2−5 studies in PsA (N=2049), and included pts treated with SEC 150 mg and SEC 300/150 mg, respectively, or placebo (PBO; Wk 16 data). Serum glucose, body mass index (BMI), TG, TC/high-density lipoprotein cholesterol (TC/HDL-C), systolic/diastolic blood pressure (BP), C-reactive protein (CRP) levels were assessed at baseline (BL), Wks 16, 104 and 156 in overall population and in sub-groups by prior anti-TNF therapy and concomitant methotrexate (MTX) usage.

 

Results: BL characteristics were generally comparable across SEC and PBO groups in both disease cohorts. Serum glucose, systolic/diastolic BP, BMI, and lipid (TG, TC/HDL) levels were minimally altered in SEC treated pts with AS and PsA through Wk 156 (Table); mean change from BL in AS: TG (mmol/L) = 0.1­­−0.2, TC/HDL-C = ±0.2, glucose (mmol/L) = 0.08−0.2, BMI (kg/m2) = 0.08−0.9, BP (mmHg) = ±0.2/±0.9 (systolic/diastolic) and mean change from BL in PsA: TG (mmol/L) = 0.003−0.2, TC/HDL-C = ±0.2, glucose (mmol/L) = ±0.3, BMI (kg/m2) = 0.1−1.7, BP (mmHg) = ±4.0/±1.0 (systolic/diastolic). CRP reductions were observed through Wk 156 (Table). Results were broadly similar in sub-groups by prior anti-TNF therapy and concomitant MTX use through Wk 156.

Conclusion: Secukinumab was associated with minimal changes in cardio-metabolic parameters over 3 years in patients with ankylosing spondylitis and psoriatic arthritis. These findings suggest that anti-IL-17 therapy may be an option in patients with cardio-metabolic risk factors, however, further research is needed.

 References:

  1. Papagoras C, et al. Joint Bone Spine. 2014;81:57-63
  2. Wolk R, et al. J Clin Lipidol. 2017;11:1243-56
  3. Agca R, et al. J Rheumatol. 2017; 44(9):1362-8


Table

Table: Key Cardio-metabolic parameters in AS and PsA pts through Wk 156 -Overall population-

Disclosure: I. McInnes, Abbott, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Roche., 2, 8, Abbvie, 5, AbbVie, 2, 5, 8, Amgen, 2, 5, 8, Astra Zeneca, 2, 5, AstraZeneca, 5, BI, 2, 5, BMS, 2, 5, 8, Boehringer Ingelheim, 5, Celgene, 2, 5, 8, Eli Lilly, 2, 5, 8, Janssen, 2, 5, 8, Leo, 5, Lilly, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, UCB, 2, 5, 8; D. Gladman, AbbVie, 2, 5, Amgen, 2, 5, BMS, 5, Celgene, 2, 5, Eli Lilly, 2, 5, Galapagos, 5, Galapagos NV, 5, Gilead, 5, GSI, 5, Janssen, 5, Janssen Research & Development, LLC, 2, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5; A. Deodhar, AbbVie, 2, 5, 9, Abbvie, 5, 8, Abbvie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, and UCB Pharma, 5, 8, AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GSK, Galapagos, Janssen, Novartis, Pfizer and UCB, 5, AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Glaxo Smith and Klein, Janssen, Novartis, Pfizer, UCB, 5, Amgen, 5, 8, 9, BMS, 2, 5, 8, BMS, Eli Lilly, Glaxo Smith & Kline, Janssen, Novartis, Pfizer, UCB, 2, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, UCB Pharma, 2, Boehringer Ingelheim, 5, 8, Boehringer-Ingelheim, 5, 8, Bristol Myers Squibb, 2, 5, Bristol-Myers Squibb, 2, 5, 8, Eli Lilly, 2, 5, 8, 9, Eli Lilly and Company, 2, 5, Eli Lilly,, 5, Eli Lilly, GSK, Novartis, Pfizer and UCB, 2, Galagagos, 5, Galapagos, 5, 8, 9, Glaxo Smith & Klein, 2, Glaxo Smith & Kline, 2, 5, 8, Glaxo Smith Klein, 5, Glaxo SmithKlein, 2, 5, GlaxoSmithKlein, 2, 5, GlaxoSmithKline, 2, 5, 8, GSK, 2, 5, Janssen, 2, 5, 8, 9, Janssen Pharmaceutica, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Novartis, 2, 5, 8, 9, Pfizer, 2, 5, 8, 9, UCB, 2, 5, 8, 9; C. Miceli-Richard, Abbott, Bristol-Myers Squibb, Merck, Pfizer, Roche, Schering-Plough, and Wyeth, 8, Abbvie, 2, 5, AbbVie, Bristol-Myers Squibb, Novartis, Merck, Pfizer, and Wyeth, 2, Biogen, 2, BMS, 5, MSD, 2, Novartis, 2, 5, Pfizer, 2, Pfizer, Roche, UCB, Wyeth, and Merck, 5, UCB, 2; P. Nash, AbbVie, 2, 5, 8, Abbvie, 2, 8, Amgen, 2, 5, 8, BMS, 2, 5, 8, Celgene, 2, 5, 8, Eli Lilly, 2, 5, 8, Gilead, 2, 5, 8, Janssen, 2, 5, 8, Lilly, 2, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, 8, Roche, 2, 5, 8, Sanofi, 2, 5, 8, UCB, 2, 5, 8; N. Sattar, Amgen, 5, Astrazeneca, 5, BI, 2, 5, 8, Boehringer Ingelheim, 2, 5, Eli Lilly, 5, 8, Janssen, 5, 8, Napp Pharmaceuticals, 5, Novo Nordisk, 5, 8, Sanofi, 5, 8; N. Mehta, AbbVie, 2, Abbvie, 2, Celgene, 2, Jannsen, 2, Janssen, 2, Novartis, 2, 5, US government, 3; D. Asquith, Novartis, 1, 3; J. Wang, Novartis, 1, 3; H. Richards, Novartis, 1, 3; L. Pricop, Noavrtis, 1, 3, Novartis, 1, 3, 4; A. Shete, Novartis, 1, 3.

To cite this abstract in AMA style:

McInnes I, Gladman D, Deodhar A, Miceli-Richard C, Nash P, Sattar N, Mehta N, Asquith D, Wang J, Richards H, Pricop L, Shete A. Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/effect-of-long-term-treatment-with-secukinumab-on-cardio-metabolic-profile-in-patients-with-active-ankylosing-spondylitis-and-psoriatic-arthritis-pooled-3-year-analysis/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-long-term-treatment-with-secukinumab-on-cardio-metabolic-profile-in-patients-with-active-ankylosing-spondylitis-and-psoriatic-arthritis-pooled-3-year-analysis/